One of the hallmarks of multiple myeloma (MM), a cancer of the bone marrow and one of the most frequent haematological cancers worldwide, is the disruption of the patients’ immune system, which allows the cancer to progress. Now, a study performed by Cristina João, who leads the Myeloma and Lymphoma Research Group at the Champalimaud Centre for the Unknown, and her colleagues, shows how so-called extracellular vesicles (EV’s) released by multiple myeloma cells can drive the disruption of the immune system.

Adjuvant cancer treatments are the most conventional, most classic therapeutic approach to cancer. Here, the first step is usually surgery to remove the tumour, followed by chemotherapy, radiotherapy or other additional treatments to consolidate the surgery’s results.

It is with great enthusiasm that we invite you to register for the second hybrid edition of CRSy, to be held at the Champalimaud Centre for the Unknown (CCU), in a stunning setting on the waterfront in Lisbon, Portugal, from October 19–21.